LONG MINI-FUTURE - BIOGEN IDEC | Delayed Deutsche Boerse AG 02:02:14 2024-05-22 pm EDT | ||
| 3.86 EUR | +1.05% |
|
| Current month | +27.81% | ||
| 1 month | +244.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 3.86 | +1.05% |
| 24-05-21 | 3.82 | -11.16% |
| 24-05-20 | 4.3 | +4.12% |
| 24-05-17 | 4.13 | +0.24% |
| 24-05-16 | 4.12 | -12.90% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 02:02 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VX4C7W |
| ISIN | DE000VX4C7W5 |
| Date issued | 2021-12-06 |
| Strike | 185.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.99 € |
|---|---|
| Lowest since issue | 0.57 € |
| Spread | 0.21 € |
| Spread % | 5.33% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
225.2
USD
Average target price
287.3
USD
Spread / Average Target
+27.57%
- Stock Market
- Certificates
- Certificat
